Will the consolidation in biologics manufacture continue?

By Ben Hargreaves contact

- Last updated on GMT

(Image: Getty/Robert Daly)
(Image: Getty/Robert Daly)
This year has seen some major trends across the industry, with a significant amount of deals seeing the biologics CDMO market consolidating.

In terms of deals, much of the focus has been on the cell and gene therapy space – which is one of the fastest developing areas, with the cell therapy market alone expected to triple in size by 2025​.

As a result, the larger companies in the contract development and manufacturing organization (CDMO) space have been making acquisitions to bolster their offerings in cell and gene therapy.

First, Catalent acquired Paragon for $1.2bn (€1.09bn) to add to its viral vector capacity and, the following month, Thermo Fisher Scientific invested $1.7bn (€1.54bn) to acquire Brammer Bio​, bolstering its gene therapy offerings.

In a larger deal for the market, Danaher decided to spend $21bn to acquire GE BioPharma​, a further sign of the strength of optimism in the future of the biologics space.

The question is whether such consolidation is set to continue, as CDMO players look to establish themselves as the leaders in the area.

Have your say in the poll below:

Will the consolidation continue?
It is likely to accelerate
Created with Poll Maker

Related news

Show more

Related products

show more

Rapid Biosafety Testing Enables the Future of Manufacturing

Rapid Biosafety Testing Enables the Future of Manufacturing

Viral Safety for mAb: Prevent, Detect, Remove | 05-Aug-2020 | Technical / White Paper

Traditional methods for adventitious agent testing rely on biological amplification and detection, which can take several weeks. This time-consuming approach...

Related suppliers

Follow us


View more